Core Viewpoint - China Tongfu (01763) announced a collaboration with Beijing Normal University to sign a patent transfer agreement and a cooperation agreement for the fluorine-18 labeled beta-amyloid imaging agent project, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - The fluorine-18 labeled beta-amyloid imaging agent is a new drug developed by a team led by Professor Cui Mengchao from Beijing Normal University in collaboration with China Tongfu, possessing complete independent intellectual property rights [1] - The drug has shown significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event marks a significant milestone in the collaboration between academia and industry, emphasizing the importance of transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with China Tongfu emerging as a core player in the field due to its deep industry experience and distinctive industrial characteristics [1] - Future collaborations will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to the global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]
中国同辐：附属与北师大签署氟[18F]贝他嗪一类创新核药专利转让协议及产学研项目合作协议